Surgical Robotics Technology

Novocure Appoints Dr. Nicolas Leupin as CMO

novocure-logo

Novocure has announced the appointment of Nicolas Leupin, M.D., Ph.D., MBA to the role of Chief Medical Officer. Dr. Leupin brings a proven track record of leadership and accomplishment in the biotechnology and pharmaceutical industries, as well as extensive experience as a medical oncologist and educator. At Novocure, Dr. Leupin will oversee medical affairs, medical safety, and clinical development operations as the company advances its clinical pipeline and prepares to treat an expanded patient population.

“It is a pleasure to welcome Dr. Leupin to Novocure as our new Chief Medical Officer,” said Asaf Danziger, Novocure’s Chief Executive Officer. “Nicolas brings a wealth of knowledge and experience from some of the most innovative oncology companies in the world, as well as a dedication to patients that is core to Novocure’s mission. I am confident that his expertise will be instrumental as Novocure enters its next chapter, treating patients with aggressive tumors of the brain, torso and abdomen.”

“I am thrilled to join Novocure’s executive leadership team and contribute to the innovation and expansion of this novel modality, Tumor Treating Fields therapy,” said Dr. Leupin. “2024 is a critical year for Novocure with multiple opportunities on the horizon and I am excited to be joining a company with such strong capabilities and aspirations to materially advance patient care.”

Before joining Novocure, Dr. Leupin served as the Chief Medical Officer at Molecular Partners, a clinical-stage biopharmaceutical company, where he led the development of multiple designed ankyrin repeat protein therapeutics. Prior to his time at Molecular Partners, Dr. Leupin served as the Chief Medical Officer at Argenx, a leader in the development of therapeutic antibodies, and was instrumental in the development of Vyvgart and other compounds. Before moving into executive leadership, Dr. Leupin held a number of clinical development leadership roles at Celgene in the myeloma and lymphoma programs.

Dr. Leupin earned his M.D. at the University of Bern, his Ph.D. from the UBFC-Université in France, and an MBA from Jones International University in the U.S. Dr. Leupin is a board certified medical oncologist with a specialty in hematological oncology. He has co-authored high-impact papers in peer-reviewed scientific journals, and is dedicated to educating the generation of oncologists through his continuing work as a lecturer of Tumor Biology at the University of Bern.

Dr. Leupin will assume the clinical and medical responsibilities held by Pritesh Shah, Novocure’s former Chief Growth Officer. As previously announced, Mr. Shah resigned his position as an executive officer effective January 1, 2024 and has agreed to become a Senior Advisor to the Chief Executive Officer in a non-executive capacity.

“I would like to thank Pritesh for his dedication and leadership over the 12 years,” said Asaf Danziger. “Pritesh has been at Novocure since the beginning of our commercial business and helped shape and build our business from scratch. I am very grateful to Pritesh and wish him a lifetime of happiness.”

Source: Novocure

Surgical Robotics Technology

Join thousands of Surgical Robotics Experts and get the latest updates straight to your inbox!